Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2018-11-29 Major Shareholding Noti…
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding percentage for a holder named 'Gladiator' in 'Calliditas Therapeutics AB'. The table shows the 'Before the transaction' and 'After the transaction' share counts and voting rights, culminating in a new percentage of 6.88%. The section title 'Reason for major shareholding notification' confirms the nature of the filing. This directly corresponds to the definition of a Major Shareholding Notification.
2018-11-29 English
Kallelse till extra bolagsstämma i Calliditas Therapeutics AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kallelse till extra bolagsstämma i Calliditas Therapeutics AB (publ)" which translates to 'Notice of Extraordinary General Meeting in Calliditas Therapeutics AB (publ)'. It details the date, time, location, registration requirements, agenda items (including a proposal for a long-term incentive program involving stock options), and voting requirements for an Extraordinary General Meeting (EGM). This content directly relates to the formal process of convening a shareholder meeting and soliciting votes/information for it. This aligns best with the definition of materials shared during a General Meeting or the solicitation materials leading up to it. Since it is a formal notice and agenda for a meeting where shareholder votes are solicited (especially regarding the incentive program), it strongly suggests a proxy/meeting context. The closest fit among the provided codes is AGM-R (AGM Information), as EGMs follow similar procedural documentation to AGMs, or potentially PSI (Proxy Solicitation & Information Statement). Given the explicit nature of the 'Kallelse' (Notice) and the agenda items, AGM-R is the most appropriate classification for the official notice of the meeting itself.
2018-11-14 Swedish
Notice of extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled a "Notice of extraordinary shareholders' meeting of Calliditas Therapeutics AB (publ)". It details the date, time, location, registration requirements, agenda items (including a proposal for a long-term incentive program via warrants), and voting requirements for this meeting. This content directly relates to the formal process and materials surrounding a shareholder meeting, specifically an Extraordinary General Meeting (EGM), which falls under the scope of AGM Information (AGM-R), as it concerns shareholder rights and meeting procedures, even if it's not the Annual General Meeting itself. The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (PSI), but rather the official summons and associated materials for the meeting.
2018-11-14 English
Första patienten rekryterad till den registreringsgrundande kliniska fas 3-studien NEFIGARD med ledande läkemedelskandidaten Nefecon
Investor Presentation Classification · 95% confidence The document is a press release announcing a significant corporate and clinical development: the recruitment of the first patient in a Phase 3 clinical trial (NEFIGARD) for the drug Nefecon for IgA nephropathy (IgAN). It details the study design, expected timelines (Topline data H2 2020), quotes management, and includes standard boilerplate information about the company (Calliditas Therapeutics) and the disease. This type of announcement, focusing on clinical trial progress and strategic updates, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a detailed announcement about strategy and pipeline progress, Investor Presentation (IP) is the most fitting category, as it often contains this level of strategic detail, even if presented as a press release. It is not a formal regulatory filing like 10-K or IR, nor is it a transcript (CT) or a simple earnings release (ER). It is a strategic update aimed at investors.
2018-11-13 Swedish
First patient enrolled in pivotal clinical phase 3 study NEFIGARD with lead candidate Nefecon
Earnings Release Classification · 95% confidence The document is a press release dated November 13, 2018, announcing that the first patient has been enrolled in a pivotal Phase 3 clinical study (NEFIGARD) for the drug Nefecon. It details the study design, expected timelines for top-line data (H2 2020), and includes quotes from the CEO and CMO. This type of announcement, detailing clinical trial progress and strategic updates, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a specific announcement about a major operational milestone (Phase 3 start) and includes key business context, it fits best under the 'Earnings Release' category, which often encompasses significant operational news outside of formal quarterly reports (IR) or specific financing/legal events. It is not a full financial report (10-K or IR), a transcript (CT), or a management discussion (MDA), but rather a headline announcement of progress. FY 2018
2018-11-13 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Calliditas Therapeutics AB covering the period from January 1 to September 30, 2018. It contains detailed financial statements, summaries of business activities, management commentary (VD-ord), and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2018
2018-11-01 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.